{"changeSha256":"ec045a3a9651f7191e4c4fd0a6067b37b65175744347aff77790d465fc946d2c","changedAt":"2026-07-27","changedFields":[{"after":"A mitochondria-targeting peptide candidate. This profile cites a recruiting ClinicalTrials.gov study record.","before":"A mitochondria-targeting peptide candidate represented in ClinicalTrials.gov.","field":"Profile summary"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/elamipretide/versions/2/","version":2},"id":"profile:elamipretide:v2","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-updated","notice":"We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.","peptideSlugs":["elamipretide"],"previousChangeEvent":null,"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/elamipretide/versions/1/","version":1},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"ctg-nct07531251-v4","name":"ClinicalTrials.gov","sourceClass":"A","title":"4TAZPower: Elamipretide in Participants With Barth Syndrome · record history version 4 · last update posted 2026-07-13","url":"https://clinicaltrials.gov/study/NCT07531251?a=4&tab=history","verifiedAt":"2026-07-22"}],"subject":{"slug":"elamipretide","type":"profile"}}